Overview

Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD6234

Status:
RECRUITING
Trial end date:
2026-01-08
Target enrollment:
Participant gender:
Summary
This study will evaluate the pharmacokinetics (PK), safety, and tolerability of single subcutaneous dose of AZD6234 with end stage renal disease, severe, and possibly moderate and mild renal impairment in comparison to a matched healthy control group.
Phase:
PHASE1
Details
Lead Sponsor:
AstraZeneca